Product Pathways
BCP0018 Axitinib
a small molecule tyrosine kinase inhibitor under development by Pfi
BCP0073 Masitinib
C-Kit, PDGFR and FGFR3 InhibitorKIT inhibitor, dose-dependently inhibited SCF-induced cell proliferation with an IC50 of 150 nM.
BCP0089 Pazopanib(GW-786034)
Pazopanib (GW-786034) is a second-generation multitargeted tyrosine kinase inhibitor
BCP0234 Imatinib mesylate
Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR , respectively.
BCP0274 AG13958
Axitinib is a new inhibitor of vascular endothelial growth factor (VEGF) receptors 1-3.
BCP0276 CHIR-258(Dovitinib)
Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β.
BCP0277 AMG706(Motesanib)
Motesanib(AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3, PDGFR, c-Kit.
BCP0278 MP470
MP-470 is a new tyrosine kinase inhibitor that inhibits several kinases, including KIT, PDGFR, AXL, c-Met and c-Ret.
BCP0415 BAY73-4506(Regorafenib)
BAY 73-4506 is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
BCP0428 OSI930
OSI-930 is a potent inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck with IC50 of 80 nM, 9 nM, 8 nM, 15 nM, 41 nM and 22 nM, respectively.
第一页 1 2 最后页 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.